Erschienen in:
18.02.2019 | Original Article
A multi-centre evaluation of 566 cases of ameloblastoma in Nigeria by the African Oral Pathology Research Consortium
verfasst von:
Olujide Oladele Soyele, Abdulwarith Olaitan Akinshipo, Olajumoke Ajibola Effiom, Olufemi Gbenga Omitola, Dickson Okoh, Opeyemi Sigbeku, Azeez Butali, Henry Ademola Adeola
Erschienen in:
Oral Cancer
|
Ausgabe 1-2/2019
Einloggen, um Zugang zu erhalten
Abstract
Background
Ameloblastoma is a locally aggressive odontogenic tumour (OT) that arises from odontogenic epithelium without neoplastic involvement of odontogenic ectomesenchyme. It is the commonest OT in developing countries, especially in Africa, and, hence, a clinically significant lesion among Africans. It has been suggested that the biologic behaviour of ameloblastoma in black Africans is different from the other populations. The high incidence of ameloblastoma in Africans warrants further evidence-based research.
Method
In this descriptive cross-sectional study, AOPRC employed a multi-centre approach to retrieve archival demographic and clinicopathological data on ameloblastoma from five major tertiary health institutions in South–West and South–South regions of Nigeria. Data were generated using a standardized data extraction format and analysed using Epi-info (version 7.0).
Result
From the five centres, a total of 566 cases met our study criteria. We observed that there was a slight male preponderance on ameloblastoma among the cases studies. For all types of ameloblastoma, mandibular lesions were found more frequently than maxillary ones. Most patients presented within 1–5 years of onset of jaw swelling (45.94%). There was a statistically significant higher mean duration for unicystic variants as compared to multi-cystic ameloblastoma (p = 0.0215). Overall, we also observed that the plexiform variants were the most frequently occurring and that the acanthomatous variant was significantly more common in females than males (p = 0.01).
Conclusion
The current study serves as primer and justification for the application of emerging novel molecular techniques to understand the pathobiology and basis for clinic-pathological disparity of ameloblastoma among men of African descent.